Skip to main content
OpenTrials
Completed

NCT Number: NCT04424459

Evaluation of an Opioid Decrease Strategy in Chronic

Increase in the consumption of analgesics observed in many countries with a mediatic crisis resulting in an increasingly frequent wish of patients to wean themselves from opiates. A recent update (B. Rolland 2017) suggests that upon initiation of an opioid analgesic treatment, the patient should be informed of the risk of opioid dependence and misuse. There is no clearly validated decay scheme in the event of dependence in patients with Chronic Non-Cancer Pain.

Hypotheses:

* Possibility of a rapid decrease in opioid analgesic treatments at DCNC sensitized to the risk of DOP and MOP. (Protocol implemented: Multidisciplinary assessment, workshops and information sheet on chronic pain, treatments and risk of DOP, pharmacological and nonpharmacological adaptation) * Highlight the need for additional information from patients and prescribers on the risk of DOP and MOP in DCNC.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Pain Chemically-Induced Disorders Mental Disorders Narcotic-Related Disorders Neurologic Manifestations Opioid-Related Disorders Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms Substance-Related Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Uhmontpellier

Montpellier, 34295, France

About this study

Main objective: Check if the rapid to semi-rapid regimen (- 25 to -60% dosage in 5 days of HDS) of opioid analgesics, without the use of methadone or buprenorphine agonists, in the case of DCNC at the CETD in Montpellier is efficient in the medium term (6 months).

Secondary objective:

  • With our inclusion questionnaire we wanted to check if the patients had been made aware of the risk of opiate dependence and misuse.
  • Detect the conditions of prescriptions that can promote the misuse of opiates.
  • Evaluating the different components of residual pain at 6 months (type, intensity, anxiety component and depression, function).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • chronic pain patient
  • major
  • supported at CETD

Exclusion criteria

-patient with physical and mental incapacity to participate in the study

Treatment and study plan

opioid withdrawal

Drug

The data retrieved from the patient will be encrypted and there will also be written data or written in binary form. They will be used to create an Excel table which allows me to list the data on D1 then on M + 3 then on M + 6 in order to evaluate the evolution of these data over a time interval of 6 months and this is which will be used as support in my thesis in pharmacy.

Primary outcomes

  1. Change of the dosage of opioid and co-analgesic treatments

    Time frame: 3 months and 6 months

    Change of the dosage of opioid and co-analgesic treatments

Secondary outcomes

  1. Measuring quality of life

    Time frame: Inclusion, 3 and 6 months

    interview with the patient

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Evaluation of an Opioid Decrease Strategy in Chronic Pain Patients at the Pain Assessment and Treatment Center in Montpellier: Prospective Study Over 6 Months.

Acronym: EODSCPP

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Jun 11, 2020
Registry last updated
Dec 29, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.